Alnylam Pharmaceuticals, Inc. (ALNY) company profile
Close on Nov 18, 2026Market cap $20.01BP/E 7.8Yield –
About Alnylam Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical enterprise focused on discovering and developing novel medicines utilizing ribonucleic acid interference (RNAi) to silence disease-causing genes. The company's portfolio features commercial products such as AMVUTTRA and ONPATTRO for transthyretin-mediated amyloidosis, GIVLAARI for acute hepatic porphyria, and OXLUMO for primary hyperoxaluria type 1, alongside collaborator-marketed therapies Leqvio for hypercholesterolemia and Qfitlia for hemophilia A and B. Its therapeutic solutions are designed to treat patients suffering from rare genetic ailments as well as more prevalent cardiovascular conditions.
Operating on an international scale, the organization maintains more than 20 clinical-stage research programs across multiple medical indications. Its marketed therapies have obtained regulatory clearances and distribution reach across numerous territories, including the United States, the European Union, the United Kingdom, Japan, Brazil, and China, with partner-marketed Leqvio commercialized in 89 countries worldwide. The provided excerpt does not disclose the location of the company's corporate headquarters.
Summary of the business section of Alnylam Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Alnylam Pharmaceuticals, Inc.
- Founded
- 2002
- Headquarters
- Cambridge, MA
- Address
- 675 West Kendall Street, Henri A. Termeer Square 02142
- Phone
- (617) 551-8200
- Website
- www.alnylam.com
- Employees
- 2,500, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- ALNY
- Exchange
- Nasdaq
- IPO date
- May 28, 2004
- Shares outstanding
- 134M, Oct 23, 2026
- Public float
- $42.63B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1178670
- CUSIP
- 02043Q107
- ISIN
- US02043Q1076
- FIGI
- BBG000BFGNJ5
- Share class FIGI
- BBG001S7FTC8
- LEI
- 529900S3ZI14OWRJII50
- EIN
- 77-0602661
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Yvonne Greenstreet | Chief Executive Officer, Director | 85,209 |
| Bryan Supran | EVP, CLO and Secretary | 12,807 |
| Melissa McLaughlin | Chief Human Resources Officer | 11,673 |
| Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | 21,106 |
| Jeffrey V. Poulton | EVP, Chief Financial Officer | 63,194 |
| Tolga Tanguler | EVP, Chief Commercial Officer | 34,297 |
| Pushkal Garg | EVP Chief R&D | 21,124 |
| Robert W. Hesslein | EVP, CLO and Secretary | 8,002 |
| David E. I. Pyott | Director | 33,262 |
| Charles Elliott Sigal | Director | 5,046 |
| Amy W. Schulman | Director | 25,959 |
| Benjamin Cravatt | Director | – |
| Colleen F. Reitan | Director | 1,446 |
| Peter N. Kellogg | Director | 1,446 |
| Margaret A. Hamburg | Director | 1,582 |
| Olivier Brandicourt | Director | 1,446 |
| Stuart A. Arbuckle | Director | 671 |
| Dennis A. Ausiello | Director | 5,082 |
| Michael W. Bonney | Director | 32,054 |
| Carolyn R. Bertozzi | Director | 775 |
| Phillip A. Sharp | Director | 278,149 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $14.87M | $77.43M | $6.58M | $306 | $125 |
| FY2024 | $11.49M | $29.84M | $3.03M | $181 | $93 |
| FY2023 | $8.90M | $11.41M | $2.92M | $147 | $94 |
| FY2022 | $4.59M | $19.04M | $3.58M | $183 | $90 |
| FY2021 | $10.18M | $17.51M | $5.92M | $130 | $100 |
| FY2020 | $7.82M | $10.77M | $4.24M | $113 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| Yvonne L. Greenstreet, M.D. Chief Executive Officer (principal executive officer) | $1.40M | – | $5.51M | $4.36M | $3.56M | $25.02K | $14.87M | +29% |
| Jeffrey V. Poulton Executive Vice President, Chief Financial Officer (principal financial officer) | $724.40K | – | $3.99M | $1.18M | $950.30K | $22.40K | $6.86M | +81% |
| Bryan A. Supran Executive Vice President, Chief Legal Officer and Secretary | $190.40K | $350.00K | $6.00M | – | $214.82K | $90.70K | $6.85M | – |
| Pushkal Garg, M.D. Executive Vice President, Chief Research and Development Officer | $767.90K | – | $3.69M | $940.05K | $1.07M | $22.40K | $6.49M | +122% |
| Tolga Tanguler Executive Vice President, Chief Commercial Officer | $698.00K | – | $3.69M | $940.05K | $783.20K | $20.12K | $6.13M | +123% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed approximately 2,500 full-time employees, of whom approximately 1,945 were employed in the U.S.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 6, 2015 | Deregistration | Termination of SEC registration (Form 15) |
| Jul 27, 2015 | Delisting | Notice of delisting from exchange (Form 25) |
| Apr 8, 2014 | Listing | Registration of securities on an exchange (Form 8-A) |
| Mar 6, 2014 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jun 29, 2007 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 28, 2004 | IPO | Initial public offering priced (424B4 prospectus) |
See a number that looks wrong?